Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (ADVANCE-II)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03697707 |
Recruitment Status :
Active, not recruiting
First Posted : October 5, 2018
Last Update Posted : October 10, 2022
|
Sponsor:
Mendus
Collaborator:
Amsterdam UMC, location VUmc
Information provided by (Responsible Party):
Mendus
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | March 2023 |
Estimated Study Completion Date : | December 2025 |